Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melatonin for Benzodiazepine Withdrawal in MMT Patients
NCT00261183Phase 3Unknown
- Sponsor
- Tel Aviv Sourasky Medical Center
- Start
- Dec 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of melatonin in benzodiazepine dependence (2 arms), sponsored by Tel Aviv Sourasky Medical Center. Primary endpoint: Stop benzodiazepine abuse (Urine). Status: unknown.
02
Drugs
melatonin
03
Conditions
benzodiazepine dependence
Beyond the preview
Go deeper on NCT00261183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00261183.